American Lung Association Advocates for Expanded Biomarker Testing in Lung Cancer Detection

In its recently released 2024 State of Lung Cancer report, the American Lung Association (ALA) urges states to implement policies requiring insurance companies to cover comprehensive biomarker testing for lung cancer to improve early diagnosis, when the disease is most treatable.

The report sheds light on the varied lung cancer outcomes across different states, highlighting a clear need for early diagnosis. By increasing lung cancer screening rates and extending the reach of biomarker testing, healthcare systems can detect the disease earlier and provide optimal treatments sooner. 

Harold Wimmer, MS, President and CEO of the ALA, emphasizes the significance: “Increasing lung cancer screening rates and expanding biomarker testing are enormous opportunities to catch cancer earlier and provide the best treatments for people diagnosed with the disease.”

Cizzle Bio, Inc.—Driving Innovation in Early Detection of Lung Cancer

Cizzle Bio's groundbreaking CIZ1B biomarker-based blood test is meeting the critical need for a minimally invasive, cost-effective, and highly accurate diagnostic tool for early detection of lung cancer, when treatment is most effective.  Aligning with the ALA’s recommendations, the CIZ1B biomarker test provides actionable information that enhances early intervention—leading to improved outcomes and renewed hope for patients.  We support the ALA’s call to mandate insurance coverage for biomarker testing for lung cancer and stand ready to save more lives through the power of early detection.

Read more about this important topic in the Oncology Times article here.